ALSO READStrides Shasun gets USFDA nod for drug used in dementia treatment Strides Shasun issued 3 observations from USFDA for Bangalore plant Strides Shasun advances on USFDA approval for Ibuprofen Tablets US FDA renews approval for Strides Shasun's Puducherry APIs plant Vivimed Labs & Strides Shasun to form two JVs to tap US generic market
Drug firm Strides Shasun has received an Establishment Inspection Report (EIR) from the US health regulator for its formulations facility at Bengaluru.
"The company's formulations facility (KRSG Gardens) in Bengaluru which was inspected by the USFDA in May 2017 has received the EIR, thereby confirming the closure of the inspection," Strides said in a BSE filing.
The KRSG Gardens facility manufactures tablets, capsules, liquids, sachets, creams and ointments. The facility supports important current and future products for the US market.
Shares of Strides Shasun were trading at Rs 927.50 apiece, up 2.10 per cent from the previous close on BSE.